The CREM Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast cell line, featuring targeted disruption of the CREM gene. This polyclonal knockout model provides a heterogeneous population of cells with loss-of-function mutations, enabling robust functional studies in a physiologically relevant B lymphocyte context without clonal selection biases.
The Raji cell line is a well-characterized human B lymphocyte model originally isolated from a Burkitt’s lymphoma patient. These cells are Epstein-Barr virus (EBV)-positive and exhibit characteristic features of B lymphoblasts, including robust proliferation and the capacity for antigen presentation and antibody production. As a lymphoblastoid cell line, Raji cells maintain active cAMP and CREB signaling pathways, making them highly suitable for investigating the transcriptional control of immune functions and oncogenic processes.
CREM (cAMP Responsive Element Modulator) is a transcription factor that binds cAMP response elements (CRE) in target gene promoters, translating cAMP signals into transcriptional outputs. Activation occurs through GPCR-mediated stimulation of adenylyl cyclase, elevating cAMP, and subsequent PKA phosphorylation of CREM and its dimerization partners CREB and ATF1. CREM activity is fine-tuned by interactions with CBP/p300 and the repressor isoform ICER. It directly regulates genes involved in proliferation (cyclin D1), survival (Bcl-2), immune responses (IL-2), and circadian rhythms (PER1).
In Raji B cells, CREM plays a critical role in modulating immune functions and oncogenic transformation. Its loss disrupts the transcriptional network controlling B cell activation, proliferation, and apoptosis downstream of cAMP and receptor-mediated signals. The CREM knockout Raji polyclonal model therefore provides a relevant system to investigate the molecular basis of B cell lymphomas and autoimmune pathologies, and to assess CREM as a potential drug target.
These polyclonal knockout cells are ideal for functional genomics, pathway analysis, and drug discovery. Researchers can perform transcriptomic profiling (RNA-seq, ChIP-qPCR) to identify CREM-regulated genes, validate protein expression changes via western blotting, and quantify cellular responses using flow cytometry, apoptosis assays, and CRE-luciferase reporter assays. The model also serves for drug sensitivity testing to evaluate therapeutic candidates in lymphoma. For further information, please contact Ascent Research.
